Mid-treatment tumour shrinkage predicted survival in oropharyngeal cancer
Tumour volume reduction above 40% during radiotherapy was independently associated with improved overall survival in patients with oropharyngeal cancer.
Tumour volume reduction above 40% during radiotherapy was independently associated with improved overall survival in patients with oropharyngeal cancer.
Preoperative radiotherapy was not associated with greater renal dysfunction after nephrectomy for retroperitoneal sarcoma during follow-up extending to 80 months.
Longer pembrolizumab exposure after chemoradiation was associated with lower mortality, but immortal time bias prevents causal interpretation.
Normal-tissue sparing with ultrahigh dose-rate radiotherapy remains conditional and cannot replace conformal dosimetry, organ-at-risk constraints, or rigorous quality assurance.
Concurrent chemotherapy improved progression-free survival without a significant overall survival benefit in early primary tumors with low-volume nodal disease.
Preoperative single-fraction and fractionated stereotactic radiotherapy produced similarly low composite event rates after resection of brain metastases.
Patients reported persistently worse quality of life and functioning approximately two years after chemoradiotherapy than matched individuals without cancer.